



# MEDICAL POLICY STATEMENT

## TrueCare

Policy Name & Number	Date Effective
Noninvasive Home Mechanical Ventilation-TrueCare-MM-1721	07/01/2025-11/30/2025
Policy Type	
MEDICAL	

Medical Policy Statements are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased, or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage or Certificate of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other plan policies and procedures.

Medical Policy Statements do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage or Certificate of Coverage) for the service(s) referenced in the Medical Policy Statement. Except as otherwise required by law, if there is a conflict between the Medical Policy Statement and the plan contract, then the plan contract will be the controlling document used to make the determination.

According to the rules of Mental Health Parity Addiction Equity Act (MHPAEA), coverage for the diagnosis and treatment of a behavioral health disorder will not be subject to any limitations that are less favorable than the limitations that apply to medical conditions as covered under this policy.

### Table of Contents

A. Subject.....	2
B. Background.....	2
C. Definitions .....	2
D. Policy .....	2
E. Conditions of Coverage.....	7
F. Related Policies/Rules.....	7
G. Review/Revision History.....	7
H. References.....	7

A. Subject  
**Noninvasive Home Mechanical Ventilation**

B. Background

This document outlines the medical necessity criteria for a noninvasive home ventilator for a member with stable, chronic respiratory failure. This device does not treat the underlying cause of respiratory failure but functions as supportive therapy, which may include reducing symptoms, improving quality of life, or sustaining or extending life. It may be used intermittently during the day and/or during sleep.

A noninvasive home ventilator will not be reimbursed as such when its sole purpose is to function as a respiratory assistance device, including continuous positive airway pressure (CPAP), auto-titrating PAP, and bilevel airway pressure (BiPAP).

C. Definitions

- **Apnea-Hypopnea Index (AHI)** – The combined average number of apneas and hypopneas that occur per hour of sleep to determine the severity of obstructive sleep apnea (OSA).

Apnea-Hypopnea Index (AHI)		
	Adult AHI	Pediatric AHI
<b>Mild OSA</b>	5 - 14	1 - 4.9
<b>Moderate OSA</b>	15 - 30	5 - 9.9
<b>Severe OSA</b>	> 30	> 10

- **Bi-level Positive Airway Pressure (BiPAP) Device** – A device that uses mild bi-level or 2 levels of air pressure to keep breathing airways open.
- **Continuous Positive Airway Pressure (CPAP) Device** – A device that uses mild continuous air pressure to keep breathing airways open.
- **Home Mechanical Ventilation (HMV)** – A device used in the home setting for patients with chronic respiratory failure that delivers respiratory assistance via an invasive (ie, tracheostomy) or noninvasive (ie, nose/mouth mask, mouthpiece, nasal prongs) interface. These devices possess more advanced features than a CPAP/BiPAP machine, which include monitoring, rate control, safety, and backup power features. The ventilator can custom control all phases of the breathing cycle.
- **Ventilator** – A mechanical device used to replace and/or support ventilatory lung function.

D. Policy

I. TrueCare utilizes Mississippi Division of Medicaid (MS MCD) and MCG Health criteria to determine medical necessity for noninvasive HMV (E0466). An initial approval for HMV is valid for a maximum of 3 months. A new medical necessity determination thereafter is required every 6 months for continued rental use.

II. Initial Rental of HMV

Medical necessity for the initial coverage of noninvasive HMV is based upon the following conditions in II - IV being met.

A member must have one of the qualifying diagnoses:

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

- A. Congenital central hypoventilation syndrome
- B. Chronic lung disease of infancy (eg, bronchopulmonary dysplasia) and patient unable to maintain acceptable pH and PCO<sub>2</sub> without ventilator support
- C. Chronic obstructive pulmonary disease (COPD) and **ONE OR MORE** of the following:
  - 1. Chronic hypercapnia with PaCO<sub>2</sub> of 50 mm Hg (6.7 kPa) to less than 52 mm Hg (6.9 kPa) and at least **ONE** of the following:
    - a. Arterial oxygen saturation ≤ 88% for 5 consecutive minutes during nocturnal oximetry while on at least 2 liters of oxygen per minute.
    - b. Invasive or noninvasive ventilation for acute exacerbation required during 2 or more hospitalizations per year.
  - 2. Chronic hypercapnia with PaCO<sub>2</sub> of 52 mm Hg (6.9 kPa) or greater
  - 3. Palliative care for end-stage disease and advance directive states no desire for intubation
- D. Neuromuscular disorder accompanied by chronic respiratory failure, as indicated by 1 or more of the following documentation of respiratory failure:
  - 1. Arterial O<sub>2</sub> saturation less than 88% for 5 consecutive minutes during nocturnal oximetry
  - 2. Daytime PCO<sub>2</sub> (arterial or capillary) greater than 45 mm Hg (6.0 kPa)
  - 3. Forced vital capacity less than 50% of predicted
  - 4. Forced vital capacity less than 80% of predicted and symptoms of respiratory failure
  - 5. Maximum inspiratory pressure 60 cm H<sub>2</sub>O (5884 Pa) or lower
  - 6. Maximum sniff nasal inspiratory pressure less than 40 cm H<sub>2</sub>O (3923 Pa)
  - 7. Polysomnography demonstrates sleep hypoventilation, as indicated by **ONE OR MORE** of the following:
    - a. Adult with sleep-related hypoventilation (ie, arterial, end-tidal, or transcutaneous PCO<sub>2</sub> greater than 55 mm Hg (7.3 kPa) for 10 minutes or longer, or increase in arterial, end-tidal, or transcutaneous PCO<sub>2</sub> of 10 mm Hg (1.3 kPa) or greater above awake supine value resulting in PCO<sub>2</sub> greater than 50 mm Hg (6.7 kPa) for 10 minutes or longer).
    - b. Child with sleep-related hypoventilation (ie, sleeping arterial, end-tidal, or transcutaneous PCO<sub>2</sub> of greater than 50 mm Hg (6.7 kPa) for greater than 25% of total sleep time, or peak sleep end-tidal PCO<sub>2</sub> of 55 mm Hg (7.3 kPa) or greater).
- E. Obesity hypoventilation syndrome, as indicated by **ALL** of the following:
  - 1. BMI > 30
  - 2. CPAP unsuccessful or not appropriate, as indicated by **ONE OR MORE** of the following:
    - a. Comorbid sleep-related hypoventilation (ie, arterial, end-tidal, or transcutaneous PCO<sub>2</sub> greater than 55mm Hg (7.3 kPa) for 10 minutes or longer, or increase in arterial, end-tidal, or transcutaneous PCO<sub>2</sub> of 10 mm Hg (1.3 kPa) or greater above awake supine value resulting in PCO<sub>2</sub> greater than 50 mm Hg (6.7 kPa) for 10 minutes or longer)
    - b. Intolerance of CPAP pressures necessary to correct obstructive sleep apnea (OSA) component (ie, difficulty exhaling against fixed airway pressure)

- c. Lack of resolution of hypercarbia, nocturnal desaturation, and OSA despite 3 months of CPAP use
    - d. Titration study demonstrates OSA despite CPAP 15 cm H<sub>2</sub>O (1471 Pa) that is responsive to BiPAP
  3. Daytime hypercapnia with PaCO<sub>2</sub> greater than 45 mm Hg (6.0 kPa) without other etiology (eg, kyphoscoliosis, lung parenchymal disease, myopathy, severe hypothyroidism)
  4. Sleep-disordered breathing or hypoventilation on polysomnography, as indicated by **ONE OR MORE** of the following:
    - a. Apnea-hypopnea index of 5 or greater
    - b. Increase in PaCO<sub>2</sub> during sleep by more than 10 mm Hg (1.3 kPa) above value while awake
    - c. Significant oxygen desaturation (eg, less than 90%) not explained by obstructive apneas or hypopneas
  5. TSH level does not demonstrate hypothyroidism
- F. OSA in child or adolescent and **ONE OR MORE** of the following:
  1. Mild OSA (ie, apnea-hypopnea index from 1 to 5) and **ONE OR MORE** of the following when BiPAP/CPAP has been unsuccessful or not appropriate:
    - a. achondroplasia
    - b. behavioral problems
    - c. cardiovascular disease (eg, elevated blood pressure, pulmonary hypertension)
    - d. Chiari malformation
    - e. craniofacial abnormalities
    - f. Down Syndrome
    - g. excessive daytime sleepiness
    - h. impaired cognition
    - i. inattention or hyperactivity
    - j. mucopolysaccharidoses
    - k. neuromuscular disorders
    - l. Prader-Willi syndrome
  2. Moderate or severe OSA (ie, apnea-hypopnea index greater than 5)
  3. Residual apnea-hypopnea index greater than 5 in pediatric patient after adenotonsillectomy
- G. Restrictive disorder of chest wall, as indicated by **ALL** of the following:
  1. Appropriate chest wall disorder as indicated by **ONE OR MORE** of the following:
    - a. asphyxiating thoracic dystrophy
    - b. kyphoscoliosis
    - c. other chest wall disorder accompanied by chronic respiratory failure (eg, ankylosing spondylitis, fibrothorax, post-tuberculous chest wall deformity)
  2. Documentation of respiratory failure as indicated by **ONE OR MORE** of the following:
    - a. Arterial O<sub>2</sub> saturation less than 88% for 5 consecutive minutes during nocturnal oximetry
    - b. Daytime PCO<sub>2</sub> (arterial or capillary) greater than 45 mm Hg (6.0 kPa)
    - c. Forced vital capacity less than 50% of predicted

- d. Forced vital capacity less than 80% of predicted and symptoms of respiratory failure
  - e. Maximum inspiratory pressure 60 cm H<sub>2</sub>O (5884 Pa) or lower
  - f. Polysomnography demonstrates sleep hypoventilation, as indicated by **ONE OR MORE** of the following:
    - 01. Adult with sleep-related hypoventilation (ie, arterial, end-tidal, or transcutaneous PCO<sub>2</sub> greater than 55 mm Hg (7.3 kPa) for 10 minutes or longer, or increase in arterial, end-tidal, or transcutaneous PCO<sub>2</sub> of 10 mm Hg (1.3 kPa) or greater above awake supine value resulting in PCO<sub>2</sub> greater than 50 mm Hg (6.7 kPa) for 10 minutes or longer).
    - 02. Child with sleep-related hypoventilation (ie, sleeping arterial, end-tidal, or transcutaneous PCO<sub>2</sub> of greater than 50 mm Hg (6.7 kPa) for greater than 25% of total sleep time, or peak sleep end-tidal PCO<sub>2</sub> of 55 mm Hg (7.3 kPa) or greater).
- III. Respiratory status is stable, as indicated by **ALL** of the following:
- A. Airway interface is safe with a noninvasive interface with acceptable fit.
  - B. Airway pressure requirement appropriate, as indicated by **ONE OR MORE** of the following:
    - 1. BiPAP expiratory positive airway pressure requirement is ≤ to 10 cm H<sub>2</sub>O (981 Pa).
    - 2. CPAP pressure requirement in child is ≤ 15 cm H<sub>2</sub>O (1471 Pa).
    - 3. Ventilator positive end-expiratory pressure requirement is ≤ 10 cm H<sub>2</sub>O (981 Pa).
  - C. Oxygen requirement does not exceed FiO<sub>2</sub> of 40%.
  - D. Settings are stable on chosen device.
  - E. No continuous invasive monitoring or professional supervision is required.
- IV. A BiPAP or CPAP device must NOT be clinically appropriate as indicated by **ONE OR MORE** of the following.
- A. Chronic respiratory insufficiency fails to improve with simple BiPAP device.
  - B. Infant or child does not meet the minimum body weight requirement for CPAP device.
  - C. Infant or child is not appropriate for simple BiPAP device due to setting or performance requirements, as indicated by **ONE OR MORE** of the following:
    - 1. Breath rates delivered by device not appropriate for patient.
    - 2. Compatible ventilator circuits not appropriate for patient (eg, circuit compliance, compressed volume, dead space).
    - 3. Inspiratory flows delivered by device not appropriate for patient.
    - 4. Patient does not meet ventilator minimum body weight requirements.
    - 5. Pressure range (eg, expiratory pressure, inspiratory pressure) not appropriate for patient.
    - 6. Tidal volume range delivered by device not appropriate for patient.
    - 7. Ventilator inspiratory trigger delay (ie, airway pressure rise time) not appropriate for patient.
    - 8. Ventilator inspiratory trigger sensitivity not appropriate for patient.

- D. The following setting or functionality is required by the member and is not available with simple BiPAP device:
    - 1. Alarms required by member are not available on the device.
    - 2. Daytime ventilation using mouthpiece is required.
    - 3. Pressure range delivered by device is not appropriate for member.
    - 4. Member requires volume-assured pressure support or volume control mode (eg, obesity hypoventilation syndrome).
  - E. Ventilated patient requires cough assistance via volume ventilator's breath stacking capability.
  - F. Ventilation is required 24 hours per day.
- V. HMV Continued Use
- For HMV continued use beyond the initial 3-month determination, medical necessity must be reestablished every 6 months thereafter. The following is to be provided for continued use:
- A. Re-evaluation by the treating medical professional must be completed no earlier than 61 days after initiating therapy.
  - B. Documentation of the persistence of the disease process for which HMV has been prescribed.
  - C. Medical records must document that the member is compliant with and benefitting from HMV.
  - D. At least 30 consecutive days of device data, beginning after 31 days of initiation, demonstrating that the member is utilizing the device an average of 4 hours per 24-hour period. **NOTE:** Failure of the member to consistently use HMV for an average of 4 hours per 24-hour period would demonstrate non-compliant utilization of the device for its intended purpose and expectation of benefit, which would constitute a denial in continued coverage as *not reasonable and necessary*.
  - E. Additional information as requested.
- VI. In accordance with MS MCD Administrative Code for each claim, the provider cannot legitimately receive payment until necessary supporting documents have been obtained and placed in the provider's files. These documents include the following items:
- A. A face-to-face encounter related to the primary reason for requiring HMV that occurred no more than 6 months prior to the start of services with the time and date of the encounter.
  - B. A detailed written order including the type of equipment ordered, the length of need, and the qualifying diagnosis from D. II.
  - C. Practitioner order and chart notes, which support the determination of medical necessity.
- VII. Regardless of its authorized length, a rental period ends when the rented item is no longer medically necessary.

VIII. Exclusions

- A. Any application for HMV (E0466) not meeting the criteria above will be denied as being not medically necessary, including but not limited to when its sole purpose is to function as a respiratory assistance device, including CPAP, auto-titrating PAP, and BiPAP.
- B. The HMV rental (E0466) includes all associated supplies that are required for appropriate use of the device and are not separately reimbursed. Servicing, repairs, and labor, including respiratory therapy visits, are included in the monthly rental fee and may not be submitted for separate reimbursement.

E. Conditions of Coverage

Claims for ventilators being utilized to provide CPAP or BiPAP therapy for conditions described above and are submitted with HCPCS code E0466, will be denied as not being reasonable and necessary. If a HMV is dispensed to a Member for CPAP or BiPAP therapy, the claim must be coded in accordance with CareSource policy, *Positive Airway Pressure Devices for Pulmonary Disorders Continued Rental*. All requirements in D. I.-V. of this policy must be satisfied for HMV to be considered medically necessary.

F. Related Policies/Rules

Positive Airway Pressure Devices for Pulmonary Disorders Continued Rental Ventilator, 23-209 Miss. CODE R. § 1.44 (2024)

G. Review/Revision History

	DATE	ACTION
<b>Date Issued</b>	03/26/2025	Approved at Committee
<b>Date Revised</b>		
<b>Date Effective</b>	07/01/2025	
<b>Date Archived</b>	11/30/2025	This Policy is no longer active and has been archived. Please note that there could be other Policies that may have some of the same rules incorporated and CareSource reserves the right to follow CMS/State/NCCI guidelines without a formal documented Policy.

H. References

1. Coleman JM, Wolfe LF, Kalhan R. Noninvasive ventilation in chronic obstructive pulmonary disease. *Ann Am Thorac Soc.* 2019;16(9):1091-1098. doi:10.1513/AnnalsATS.201810-657CME
2. Dudgeon D. Assessment and management of dyspnea in palliative care. UpToDate. Updated September 17, 2024. Accessed December 26, 2024. www.uptodate.com
3. Ferrell BR, Twaddle ML, Melnick A, et al. National Consensus Project clinical practice guidelines for quality palliative care guidelines, 4th edition. *J Palliative Med.* 2018;21(12):1684-1689. doi:10.1089/jpm.2018.04311684
4. Freedman N. Treatment of obstructive sleep apnea: choosing the best positive airway pressure device. *Sleep Med Clin.* 2020;15(2):205-218. doi:10.1016/j.jsmc.2020.02.007
5. Gay PC. Nocturnal ventilatory support in COPD. UpToDate. Updated June 27, 2024. Accessed March 3, 2025. www.uptodate.com

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

6. Gay PC, Owens RL; ONMAP Technical Expert Panel. Executive summary: optimal NIV Medicare access promotion: a technical expert panel report from the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. *Chest*. 2021;160(5):1808-1821. doi:10.1016/j.chest.2021.05.074
7. Hansen-Flaschen J, Ackrivo J. Practical guide to management of long-term noninvasive ventilation for adults with chronic neuromuscular disease. *Resp Care*. 2023;68(8):1123-1157. doi:10.4187/respcare.10349
8. Hill NS, Kramer NR. Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: patient selection and alternative modes of ventilatory support. UpToDate. Updated November 13, 2024. Accessed March 3, 2025. www.uptodate.com
9. Home Ventilator (Invasive or Noninvasive Interface): ACG A-0893. MCG Health. 28th ed. Accessed March 3, 2025. www.careweb.careguidelines.com
10. Khan A, Frazer-Green L, Amin R, et al. Respiratory management of patients with neuromuscular weakness: an American College of Chest Physicians clinical practice guideline and expert panel report. *Chest*. 2023;164(2):394-413. doi:10.1016/j.chest.2023.03.011
11. Kline LR. Clinical presentation and diagnosis of obstructive sleep apnea in adults. UpToDate. Updated October 9, 2024. Accessed March 3, 2025. www.uptodate.com
12. Macrea M, Oczkowski S, Rochweg B, et al. Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease: an official American Thoracic Society clinical practice guideline. *Am J Resp Crit Care Med*. 2020;202(4):e74-e87. doi:10.1164/rccm.202006-2382ST
13. Martin TJ. Noninvasive positive airway pressure therapy for obesity hypoventilation syndrome. UpToDate. Updated March 4, 2024. Accessed March 3, 2025. www.uptodate.com
14. Mitchell RB, Archer SM, Ishman SL, et al. Clinical practice guideline: tonsillectomy in children (update). *Otolaryngology Head Neck Surg*. 2019;160(1S):S1-S42. doi:10.1177/0194599818801757
15. Raveling T, Vonk J, Struik FM, et al. Chronic non-invasive ventilation for chronic obstructive pulmonary disease: review. *Cochrane Database Syst Rev*. 2021;8:CD002878. doi:10.1002/14651858.CD002878.pub3
16. Restrepo RD, Walsh BK. Humidification during invasive and noninvasive mechanical ventilation 2012: AARC clinical practice guideline. *Respir Care*. 2012;57(5):782-788. doi:10.4187/respcare.01766
17. van den Biggelaar RJM, Hazenberg A, Cobben NAM, et al. A randomized trial of initiation of chronic noninvasive mechanical ventilation at home vs in-hospital in patients with neuromuscular disease and thoracic cage disorder. *Chest*. 2020;158(6):2493-2501. doi:10.1016/j.chest.2020.07.007

Approved by DOM 04/14/2025